| Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
|
| Notes: |
Hospital only guidance
|
|
| Details... |
| 08.01.05 |
Other antineoplastic drugs |
|
|
Axitinib (tabs)
|
Formulary
 
|
|
 NICE TA333: Axitinib for advanced renal cell carcinoma
|
Bosutinib (tabs)
|
Formulary
|
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
NICE TA576 Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)
|
Carfilzomib (injection)
|
Formulary
|
MHRA:Kyprolis▼- Reminder of risk of potentially fatal cardiac events
MHRA: Risk of reactivation of hepatitis B virus
|
NICE TA457 : Carfilzomib for previously treated multiple myeloma
NICE TA657 Carfilzomib for previously treated multiple myeloma
|
Cemiplimab
(IV infusion)
|
Formulary
|
|
NICE TA592 Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
|
Ceritinib (caps)
|
Formulary
|
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
NICE TA500 Ceritinib for untreated ALK-positive non-small-cell lung cancer
|
Dabrafenib (caps)
|
Formulary
|
|
NICE TA321:Dabrafenib for BRAF V600 +ve melanoma
NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
NICE TA544 Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
|
Dacomitinib (Vizimpro)
(Tablets)
|
Formulary
|
|
NICE TA595 Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
|
Durvalumab (Imfinzi)
(Solution for infusion)
|
Formulary
|
|
NICE TA578 Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
NICE TA662 Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)
|
Entrectinib (Rozlytrek® 100mg and 200mg )
(hard capsules)
|
Formulary
|
|
TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
TA644 Enrectinib for treating NTRK fusion-positive solid tumours
|
Eribulin (injection)
|
Formulary
|
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
NICE TA515 Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
|
Ibrutinib (caps)
|
Formulary
|
|
NICE TA429 : Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
NICE TA502 Ibrutinib for treating relapsed or refractory mantle cell lymphoma
NICE TA608 Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal)
|
Idelalisib (tabs)
|
Formulary
|
|
NICE TA359: Chronic lymphocytic leukaemia - Idelalisib
|
Inotuzumab ozogamicin (Besponsa®)
|
Formulary
|
|
TA 541 Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
|
Ixazomib (Ninlaro®)
|
Formulary
|
|
NICE TA505 Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
|
Lenvatinib (Lenvima®)
|
Formulary
|
|
NICE TA498 Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
NICE TA551 Lenvatinib for untreated advanced hepatocellular carcinoma
|
Panitumumab (Vectibix®)
|
Formulary
|
|
NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
|
Panobinostat (Farydak®)
|
Formulary
|
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
|
Pembrolizumab (injection)
|
Formulary
|
|
NICE TA357: Pembrolizumab for melanoma after ipilimumab
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
NICE TA447 : Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
NICE TA519 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA522 Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
NICE TA531 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
NICE TA540 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
NICE TA553 Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
NICE TA557 Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
NICE TA570 Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal)
NICE TA600 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
NICE TA661 Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
|
Ruxolitinib (tabs)
|
Formulary
|
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
|
Trametinib (tabs)
|
Formulary
|
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
NICE TA544 Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
|
| 08.01.05 |
Amsacrine |
|
|
Amsacrine (injection)
|
Formulary
|
|
|
|
| 08.01.05 |
Arsenic trioxide |
|
|
Arsenic Trioxide (Trisenox 1mg/ml concentrate for infusion)
(injection)
|
Formulary
|
|
NICE TA526 Arsenic trioxide for treating acute promyelocytic leukaemia
|
| 08.01.05 |
Bevacizumab |
|
|
Avelumab (injection)
(Oncology)
|
Formulary
|
|
https://www.nice.org.uk/guidance/ta517
NICE TA645 Avelumab with axitinib for untreated advanced renal cell carcinoma
|
Bevacizumab (injection)
(Oncology)
|
Formulary
|
|
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)
NICE TA214: Breast Cancer with taxane
NICE TA263: Breast cancer with capecitabine
NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
|
Daratumumab (injection)
(Oncology)
|
Formulary
|
MHRA:Darzalex▼- Risk of reactivation of hepatitis B virus
|
NICE TA510 Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
NICE TA573 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
|
Tivozanib (Capsules)
(Oncology)
|
Formulary
|
|
NICE TA 512 Tivozanib for treating advanced renal cell carcinoma
|
| 08.01.05 |
Bexarotene |
|
|
| 08.01.05 |
Bortezomib |
|
|
Bortezomib (injection)
|
Formulary
|
|
NICE TA 602 Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
NICE TA129: Multiple myeloma - bortezomib
NICE TA228: 1st line treatment of multiple myeloma
NICE TA311: Bortezomib for induction therapy in multiple myeloma
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
NICE TA603 Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)
|
| 08.01.05 |
Brentuximab vedotin |
|
|
Brentuximab vedotin (injection)
|
Formulary
|
|
NICE TA446 : Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
NICE TA524 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
NICE TA564 Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal)
NICE TA577 Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
TA641 Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
|
| 08.01.05 |
Cetuximab |
|
|
Cetuximab (Erbitux®)
|
Formulary
|
|
NICE TA145: Head and neck cancer - cetuximab
NICE TA176: Colorectal cancer (first line) - cetuximab
NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
NICE TA473:Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
|
| 08.01.05 |
Crisantaspase |
|
|
Crisantaspase (Erwinase®)
|
Formulary
|
|
|
|
| 08.01.05 |
Dacarbazine and Temozolomide |
|
|
Dacarbazine (injection)
|
Formulary
|
|
|
|
Temozolomide (caps)
|
Formulary
|
|
NICE TA121: Glioma (newly diagnosed and high grade)
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
|
| 08.01.05 |
Erlotinib |
|
|
Midostaurin (Rydapt)
( Capsules)
|
Formulary
|
|
NICE TA523 Midostaurin for untreated acute myeloid leukaemia
|
| 08.01.05 |
Hydroxycarbamide |
|
|
Hydroxycarbamide
|
Formulary
|
Traffic light information
| Traffic light |
Details |
| Shared care |
Patients with myeloproliferative disorders needing cytoreduction |
| Red |
Oncology related indications |
|
SNEE ICS Hydroxycarbamide SCA (Adults) for use in myloproliferative disorders and sickle cell disease
|
| 08.01.05 |
Imatinab |
|
|
| 08.01.05 |
Ipilimumab |
|
|
Ipilimumab (injection)
|
Formulary
|
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
|
| 08.01.05 |
Mitotane |
|
|
| 08.01.05 |
Panitumumab |
|
|
| 08.01.05 |
Pentostatin |
|
|
Pentostatin (injection)
|
Formulary
|
|
|
|
| 08.01.05 |
Platinum compounds |
|
|
Carboplatin
|
Formulary
|
|
|
|
Cisplatin (injection)
|
Formulary
|
|
|
|
Oxaliplatin
|
Formulary
|
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
|
| 08.01.05 |
Porfimer sodium and temoporfin |
|
|
| 08.01.05 |
Procarbazine |
|
|
Procarbazine (caps)
|
Formulary
|
|
|
|
| 08.01.05 |
Protein kinase inhibitors |
|
|
Afatinib (tabs)
|
Formulary
|
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
|
Brigatinib (Alunbrig)
(Tablets)
|
Formulary
|
|
NICE TA571 Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
|
Cabozantinib (Cometriq®)
|
Formulary
|
|
NICE TA463 : Cabozantinib for previously treated advanced renal cell carcinoma
NICE TA516 Cabozantinib for treating medullary thyroid cancer
NICE TA542 Cabozantinib for untreated advanced renal cell carcinoma
NICE TA582 Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal)
|
Crizotinib (caps)
|
Formulary
|
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance
NICE TA529 Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
|
Dasatinib (tabs)
|
Formulary
|
|
NICE TA241: CML where treatment with imatinib has failed
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Everolimus (Afinitor®)
|
Formulary
|
|
NICE TA348: Preventing Rejection in Liver Transplant
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
|
Gilteritinib (Xospata ®)
(40 mg film-coated tablets)
|
Formulary
|
|
TA642 Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
|
Imatinib (tabs, caps)
|
Formulary
|
|
|
|
Lapatinib
(tabs)
|
Formulary
|
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
|
Nilotinib
|
Formulary
|
|
NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Pazopanib (tabs)
|
Formulary
|
|
NICE TA215: Pazopanib in renal cell cancer
|
Regorafenib (tabs)
|
Formulary
|
|
NICE TA514 Regorafenib for previously treated advanced hepatocellular carcinoma
NICE TA555 Regorafenib for previously treated advanced hepatocellular carcinoma
|
Sorafenib (tabs)
|
Formulary
|
|
|
|
Sunitinib (caps)
|
Formulary
|
|
NICE TA169: Renal cell carcinoma - sunitinib
NICE TA179: Gastrointestinal stromal tumours - sunitinib
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
|
Temsirolimus (injection)
|
Formulary
|
|
|
|
Vandetanib (tabs)
|
Formulary
|
See below for further information for educational material for the following areas
- Serious risks for adults paedeatric patients
- DOsing and monitoring guidance for paediatric patients
|
NICE TA550 Vandetanib for treating medullary thyroid cancer
Risk minimisation information for healthcare professionals
|
Vemurafenib (tabs)
|
Formulary
|
|
NICE TA269: Vemurafenib for treating malignant melanoma
|
| 08.01.05 |
Taxanes |
|
|
Cabazitaxel (Jevtana®)
|
Formulary
|
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
|
Docetaxel
|
Formulary
|
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
NICE TA109: Breast cancer (early) - docetaxel
|
Paclitaxel
|
Formulary
|
|
NICE TA108: Breast cancer (early) - paclitaxel
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
|
Paclitaxel - Albumin Bound Formulation (Abraxane®)
|
Formulary
|
|
NICE TA360: Pancreatic cancer - paclitaxel with gemcitabine
|
| 08.01.05 |
Topoisomerase I inhibitors |
|
|
Irinotecan Hydrochloride (injection)
|
Formulary
|
MHRA:Onivyde (irinotecan, liposomal formulations): reports of serious and fatal thromboembolic events
|
|
|
Topotecan (caps, injection)
|
Formulary
|
|
NICE TA183: Cervical cancer (recurrent) - topotecan
NICE TA184: Lung cancer (small-cell) - topotecan
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
|
| 08.01.05 |
Trabectedin |
|
|
Trabectedin (injection)
|
Formulary
|
|
NICE TA185: Soft tissue sarcoma - trabectedin
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
|
| 08.01.05 |
Trastuzumab |
|
|
Pertuzumab (Perjeta®)
|
Formulary
|
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
TA509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
|
Trastuzumab
|
Formulary
|
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
NICE TA34: Breast cancer - trastuzumab
TA509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
|
Trastuzumab emtansine
|
Formulary
|
|
NICE TA458 : Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxan
TA632 Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
|
| 08.01.05 |
Tretinoin |
|
|
| 08.01.05 |
Vismodegib |
|
|
Niraparib (caps)
(100mg)
|
Formulary
|
|
NICE TA528 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
|
Vismodegib (caps)
|
Formulary
|
|
|
|
| .... |
| Non Formulary Items |
Aflibercept (Zaltrap®)
|
Non Formulary
|
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
|
Alectinib (Alecensa®)
|
Non Formulary
|
|
|
|
Bexarotene (Targretin®)
|
Non Formulary
|
|
|
|
Carboplatin (Paraplatin®)
|
Non Formulary
|
|
|
|
Mitotane (Lysodren®)
|
Non Formulary
|
|
|
|
Necitumumab (Portrazza®)
|
Non Formulary
|
|
NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
|
Olaratumab
|
Non Formulary
|
MHRA: Withdrawal of the EU marketing authorisation due to lack of efficacy
Do not start new patients on olaratumab
For patients currently on treatment, consider alternative treatment options since available stock will expire by April 2020 |
NOCE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
|
Oxaliplatin (Eloxatin®)
|
Non Formulary
|
|
|
|
Pablociclib (Ibrance®)
|
Non Formulary
|
|
|
|
Paclitaxel (Taxol®)
|
Non Formulary
|
|
|
|
Ponatinib (Iclusig®)
|
Non Formulary
|
MHRA: Reports of posterior reversible encephalopathy syndrome |
NICE TA451 : Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
|
Porfimer Sodium (Photofrin ®)
|
Non Formulary
|
|
|
|
Ramucirumab (Cyramza®)
|
Non Formulary
|
|
NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
NICE TA609 Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)
|
Rociletinib
|
Non Formulary
|
|
|
|
Sonidegib (Odomzo®)
|
Non Formulary
|
|
|
|
Talimogene laherparepvec (Imlygic®)
|
Non Formulary
|
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
|
Temoporfin (Foscan®)
|
Non Formulary
|
|
|
|
Tretinoin (Vesanoid®)
|
Non Formulary
|
|
|
|
Vosaroxin (Qinprezo)
|
Non Formulary
|
|
|
|
| |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
|
|
|
